AstraZeneca revenues up as it delivers jab to 120 countries via Covax

Quarterly results from Anglo-Swedish producer of Covid vaccine show better-than-expected 15% rise

AstraZeneca has generated $275m (£197m) in revenues from its Covid vaccine in the first three months of the year and shipped 48m doses to 120 countries through the global vaccine-sharing initiative Covax.

Most of the vaccine sales ($224m) were in Europe – as the Anglo-Swedish drugmaker reported overall quarterly revenues up 15% to $7.3bn, better than analysts had expected. New medicines, such as the diabetes drug Farxiga, contributed more than half of revenues. The firm made a pre-tax profit of $1.6bn, up 72% year-on-year.

Continue reading...

Coronavirus | The Guardian

Comments

Popular posts from this blog

Vaccine hesitant New Yorkers consider leaving the city as mandates take effect

Coronavirus live news: AstraZeneca reports vaccine shortfall to EU; Sydney hotel quarantine worker tests positive

Brentford manager calls for weekend shutdown in Premier League Covid fight